U.S. markets close in 24 minutes
  • S&P 500

    3,692.36
    +25.64 (+0.70%)
     
  • Dow 30

    30,163.44
    +193.92 (+0.65%)
     
  • Nasdaq

    12,443.99
    +66.81 (+0.54%)
     
  • Russell 2000

    1,887.28
    +38.58 (+2.09%)
     
  • Crude Oil

    46.00
    +0.36 (+0.79%)
     
  • Gold

    1,840.10
    -1.00 (-0.05%)
     
  • Silver

    24.26
    +0.13 (+0.53%)
     
  • EUR/USD

    1.2137
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • GBP/USD

    1.3435
    -0.0018 (-0.13%)
     
  • USD/JPY

    104.1320
    +0.2720 (+0.26%)
     
  • BTC-USD

    18,929.31
    -328.27 (-1.70%)
     
  • CMC Crypto 200

    372.05
    -7.19 (-1.90%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

ROSEN, A LONGSTANDING INVESTOR RIGHTS LAW FIRM, Encourages Neovasc Inc. Investors with Large Losses to Contact Counsel Before Important Deadline in Securities Class Action - NVCN

·3 min read

NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Neovasc Inc. (NASDAQ:NVCN) between November 1, 2019 and October 27, 2020, inclusive (the "Class Period") of the important January 5, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Neovasc investors under the federal securities laws.

To join the Neovasc class action, go to http://www.rosenlegal.com/cases-register-1976.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the results of COSIRA, Neovasc's clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) blinding is critical when studying a placebo-responsive condition such as angina; (4) the lack of blinding assessment made the primary endpoint difficult to interpret; (5) as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) as a result, the Company's Premarket Approval application (PMA) for Reducer was unlikely to be approved without additional clinical data; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1976.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: The Rosen Law Firm, P.A.



View source version on accesswire.com:
https://www.accesswire.com/617008/ROSEN-A-LONGSTANDING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Neovasc-Inc-Investors-with-Large-Losses-to-Contact-Counsel-Before-Important-Deadline-in-Securities-Class-Action--NVCN